| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sanjeev Choudhary, Geetu Raheja, Vandana Gupta, Kiran Dip Gil. Possible involvement of dopaminergic neurotransmitter system in dichlorvos induced delayed neurotoxicity. Journal of biochemistry, molecular biology, and biophysics : JBMBB : the official journal of the Federation of Asian and Oceanian Biochemists and Molecular Biologists (FAOBMB). vol 6. issue 1. 2002-10-09. PMID:12186780. |
administration of nimodipine, a centrally acting calcium channel blocker, along with dichlorvos restricted all these alterations to within control values and could also ameliorate certain behavioural deficits by maintaining the dopaminergic neurotransmitter system. |
2002-10-09 |
2023-08-12 |
rat |
| Lynette D Fairbanks, Gabriella Jacomelli, Vanna Micheli, Tina Slade, H Anne Simmond. Severe pyridine nucleotide depletion in fibroblasts from Lesch-Nyhan patients. The Biochemical journal. vol 366. issue Pt 1. 2002-10-08. PMID:11996669. |
nad plus atp depletion in developing brain could restrict dna repair, leading to neuronal damage/loss by apoptosis, and, with gtp depletion, affect neurotransmitter synthesis and basal ganglia dopaminergic neuronal systems. |
2002-10-08 |
2023-08-12 |
human |
| M J Arranz, D Collier, R W Kerwi. Pharmacogenetics for the individualization of psychiatric treatment. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. vol 1. issue 1. 2002-09-18. PMID:12173312. |
these include the dopaminergic and serotonergic receptors, neurotransmitter transporters and other receptors and enzymes involved in psychiatric disorders. |
2002-09-18 |
2023-08-12 |
Not clear |
| Jonas Bergquist, Lil Träskman-Bendz, Mats B Lindström, Rolf Ekma. Suicide-attempters having immunoglobulin G with affinity for dopamine in cerebrospinal fluid. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 12. issue 2. 2002-08-14. PMID:11872333. |
the results in the present study indicate that an autoimmune mechanism may be involved in the dopaminergic neurotransmitter system and may be of pathophysiological importance in psychiatric disorders connected to an attempt of suicide. |
2002-08-14 |
2023-08-12 |
human |
| A Czyrak, A Chocy. Search for the presence of glucocorticoid receptors in dopaminergic neurons of rat ventral tegmental area and substantia nigra. Polish journal of pharmacology. vol 53. issue 6. 2002-07-19. PMID:11985346. |
above anatomical data indicate that glucocorticoid receptors influence the dopaminergic neurotransmission by an indirect mechanism, which possibly involves intermittent neurotransmitter. |
2002-07-19 |
2023-08-12 |
rat |
| D M Wu, H Kawamura, Q Li, D G Pur. Dopamine activates ATP-sensitive K+ currents in rat retinal pericytes. Visual neuroscience. vol 18. issue 6. 2002-07-08. PMID:12020084. |
because dopaminergic neurites are closely associated with microvessels that express dopamine receptors, this molecule is a putative neuron-to-capillary signal, as well as neurotransmitter. |
2002-07-08 |
2023-08-12 |
rat |
| Michael L Kirby, Rebecca L Barlow, Jeffrey R Bloomquis. Selective effects of cyclodiene insecticides on dopamine release in mammalian synaptosomes. Toxicology and applied pharmacology. vol 181. issue 2. 2002-07-02. PMID:12051992. |
release assays with different transmitters indicated that striatal dopaminergic terminals are severalfold more sensitive to release than other neurotransmitter types. |
2002-07-02 |
2023-08-12 |
Not clear |
| Anthony R West, Matthew P Galloway, Anthony A Grac. Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse (New York, N.Y.). vol 44. issue 4. 2002-06-24. PMID:11984858. |
an important role for the reactive gas nitric oxide (no) in regulating striatal dopaminergic neurotransmission was identified shortly after initial observations indicated that this unorthodox neurotransmitter mediates many of the influences of glutamatergic neurotransmission in the cerebellum, cortex, and hippocampus. |
2002-06-24 |
2023-08-12 |
Not clear |
| T Araki, M Matsubara, K Fujihara, H Kato, Y Imai, Y Itoyam. Gamma-aminobutyric acidA and benzodiazepine receptor alterations in the rat brain after unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. Neurological research. vol 24. issue 1. 2002-06-21. PMID:11783749. |
thus, investigations into possible changes in neurotransmitter receptors other than dopaminergic receptors appear to be important for the elucidation of pathogenesis of parkinsons disease. |
2002-06-21 |
2023-08-12 |
rat |
| T A Slotkin, C A Tate, M M Cousins, F J Seidle. Functional alterations in CNS catecholamine systems in adolescence and adulthood after neonatal chlorpyrifos exposure. Brain research. Developmental brain research. vol 133. issue 2. 2002-05-23. PMID:11882346. |
we then examined the impact on catecholaminergic systems in adolescence (pn30) and adulthood (pn60), assessing basal neurotransmitter content and transmitter utilization rates (turnover) in brain regions comprising the major noradrenergic and dopaminergic projections. |
2002-05-23 |
2023-08-12 |
rat |
| Toshihiko Morimoto, Kenji Hashimoto, Hiroshi Yasumatsu, Hiroshi Tanaka, Masatake Fujimura, Makoto Kuriyama, Koreichi Kimura, Shuzo Takehara, Keiji Yamagam. Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate). Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 26. issue 4. 2002-05-09. PMID:11927170. |
similar to clozapine and olanzapine, y-931 interacted with multiple neurotransmitter receptors such as dopaminergic, serotonergic, alpha-adrenergic, muscarinic and histaminergic receptors. |
2002-05-09 |
2023-08-12 |
rat |
| B Dea. Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue. Postgraduate medical journal. vol 78. issue 917. 2002-04-18. PMID:11884695. |
recent findings have shown changes in markers in a number of neurotransmitter systems in the brains of subjects with schizophrenia which include the dopaminergic, serotonergic, cholinergic, glutamatergic, and gabaergic systems of the cns. |
2002-04-18 |
2023-08-12 |
human |
| S Jiang, R Xin, S Lin, Y Qian, G Tang, D Wang, X W. Linkage studies between attention-deficit hyperactivity disorder and the monoamine oxidase genes. American journal of medical genetics. vol 105. issue 8. 2002-03-05. PMID:11803531. |
molecular genetic and pharmacological studies suggest the involvement of dopaminergic and noradrenergic neurotransmitter systems in adhd, e.g., several reports have found association between adhd and the dopamine receptor gene drd-4, the dopamine transporter gene dat1, and the catecholamine clearance enzyme catechol-o-methyltransferase. |
2002-03-05 |
2023-08-12 |
Not clear |
| S R Pliszk. New developments in psychopharmacology of attention deficit hyperactivity disorder. Expert opinion on investigational drugs. vol 10. issue 10. 2002-02-28. PMID:11772286. |
some, like the stimulants, primarily impact the noradrenergic and dopaminergic neurotransmitter systems, while others have novel effects on the cholinergic, histaminergic and peptidergic systems. |
2002-02-28 |
2023-08-12 |
Not clear |
| S Katsuragi, A Kiyota, T Tsutsumi, K Isogawa, H Nagayama, T Arinami, J Akiyosh. Lack of association between a polymorphism in the promoter region of the dopamine D2 receptor and personality traits. Psychiatry research. vol 105. issue 1-2. 2002-02-26. PMID:11740982. |
disturbances of the dopaminergic neurotransmitter system have been associated with a personality trait that involves novelty seeking. |
2002-02-26 |
2023-08-12 |
Not clear |
| Pawel Grieb, Robert Rejda. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. Journal of neuroscience research. vol 67. issue 2. 2002-02-21. PMID:11782957. |
furthermore, citicoline stimulates some brain neurotransmitter systems, including the dopaminergic system, and dopamine is known as a major neurotransmitter in retina and postretinal visual pathways. |
2002-02-21 |
2023-08-12 |
Not clear |
| A D Zurn, H R Widmer, P Aebische. Sustained delivery of GDNF: towards a treatment for Parkinson's disease. Brain research. Brain research reviews. vol 36. issue 2-3. 2002-02-08. PMID:11690619. |
although symptomatic therapies to substitute for the missing neurotransmitter dopamine are efficient at the early stages of the disease, the goal is to find alternative therapies which could protect dopaminergic neurons from the degenerative process. |
2002-02-08 |
2023-08-12 |
monkey |
| G A Carvalho, G Nikkha. Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Experimental neurology. vol 171. issue 2. 2001-12-05. PMID:11573992. |
these findings may therefore provide new insights into the functional interaction between the glutamatergic and the dopaminergic neurotransmitter systems and foster novel therapeutic concepts for the early and middle phases of parkinson's disease. |
2001-12-05 |
2023-08-12 |
rat |
| A Heller, N Bubula, A Freeney, L Wo. Elevation of fetal dopamine following exposure to methamphetamine in utero. Brain research. Developmental brain research. vol 130. issue 1. 2001-12-04. PMID:11557103. |
this increase in fetal dopamine is consistent with our findings that exposure to methamphetamine in utero results in adult dopaminergic neurons which are more responsive in terms of methamphetamine induced release of the neurotransmitter and more sensitive to the neurotoxic effects of the drug. |
2001-12-04 |
2023-08-12 |
mouse |
| R R Gainetdinov, A R Mohn, L M Bohn, M G Caro. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America. vol 98. issue 20. 2001-12-04. PMID:11572967. |
the dopamine transporter (dat), which reuptakes the released neurotransmitter into presynaptic terminals, is a major determinant of the intensity and duration of the dopaminergic signal. |
2001-12-04 |
2023-08-12 |
mouse |